Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 1,999 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: carboplatin Clear all

Conditions: Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions: Adjuvant Therapy, Carboplatin, Paclitaxel, Pegfilgrastim; Procedure · Drug · Biological
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 11
States / cities: Orange, California • Iowa City, Iowa • Camden, New Jersey + 6 more

Conditions: Lung Cancer
Interventions: carboplatin, chemotherapy, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 47
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more

Conditions: Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma
Interventions: Cytoreductive Surgery (CRS), Adjuvant Chemotherapy, Questionnaire, Hyperthermic intraperitoneal chemotherapy, Carboplatin, Paclitaxel, Cisplatin; Procedure · Drug · Other
Lead sponsor: Mercy Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Untreated Advanced Non-Small Cell Lung Cancer
Interventions: Avastin, Alimta; Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Carboplatin, Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration; Drug · Biological · Radiation + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Lazertinib, Amivantamab, Pemetrexed, Carboplatin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 28
States / cities: Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more

Conditions: NSCLC
Interventions: Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Gemcitabine; Drug
Lead sponsor: EQRx International, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 8
States / cities: Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more

Conditions: Brain and Central Nervous System Tumors
Interventions: carboplatin, irinotecan hydrochloride, radiation therapy; Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
Interventions: Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib, 5-Fluorouracil, Cisplatin, Paclitaxel, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 14
States / cities: Anchorage, Alaska • Duarte, California • Orange, California + 11 more

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more

Conditions: Lymphoma
Interventions: carmustine, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, irradiation therapy, G-CSF, Cytarabine; Drug · Procedure · Radiation + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 75 Years
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: filgrastim, carboplatin, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2001
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Nasopharyngeal Carcinoma
Interventions: Penpulimab, placebo; Drug
Lead sponsor: Akeso; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Duarte, California • Atlanta, Georgia • Ann Arbor, Michigan + 1 more

Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions: Paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Veliparib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania • Reading, Pennsylvania

Conditions: Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma, Stage IV Lung Adenocarcinoma, Stage IV Squamous Cell Lung Carcinoma
Interventions: Bevacizumab, Carboplatin, Cetuximab, Laboratory Biomarker Analysis, Paclitaxel; Biological · Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 797
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 473 more

Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Interventions: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 87
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more

Conditions: Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Placebo, Sorafenib Tosylate; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 823 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 218
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 175 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Carboplatin, GM-CSF (Sargramostim), Interferon Gamma; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: Imetelstat Sodium (GRN163L); Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 4
States / cities: Baltimore, Maryland • Dallas, Texas • Houston, Texas + 1 more

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Pemetrexed, Carboplatin, Paclitaxel, Bevacizumab; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 45
States / cities: Scottsdale, Arizona • Tucson, Arizona • Mission Hills, California + 42 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: CP-751,871, paclitaxel, carboplatin, erlotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 26
States / cities: Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more

Conditions: Oropharyngeal Squamous Cell Carcinoma
Interventions: Transoral Robotic Surgery (TORS) or Radiotherapy, Chemotherapy and Low-Dose Radiotherapy, Chemotherapy and High-Dose Radiotherapy, Paclitaxel, Carboplatin; Other · Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: Lapatinib, Topotecan; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2
Interventions: Paclitaxel + Carboplatin, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

HOT: HIPEC in Ovarian Cancer as Initial Treatment

Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

Study of Participants With Advanced Non-Small Cell Lung Cancer

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial